Skip to main content
main-content

14-12-2019 | Breast cancer | Video

SABCS 2019 | Neoadjuvant ribociclib plus letrozole promising in high-risk luminal B breast cancer

Joaquín Gavilá highlights the phase 2 SOLTI-1402/CORALLEEN trial findings demonstrating comparable clinical benefit and reduced toxicity of combined neoadjuvant endocrine and CDK 4/6 inhibitor therapy versus chemotherapy in patients with high-risk luminal B breast cancer (2:44).

Funding for independent interviews at SABCS 2019 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.